Tenon Medical, Inc. Announces Timing of Second Quarter 2024 Financial Results
LOS GATOS, CA / ACCESSWIRE / July 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company...
News
Georgiamune Announces First Patient Dosed in A First-In-Class Phase 1 Cancer Treatment Trial of GIM-531
GAITHERSBURG, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first...
Nascent Biotech Presents at the July Emerging Growth Conference
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM...
Bicycle Health offers first-ever virtual medication for opioid use disorder treatment for teens with new program in Maine
16- and 17-year-olds in Maine can access the nation’s leading telehealth-based treatment platform, receive the gold standard of care with...
Envision Pharma Group Announces the Appointment of Bill Shirey to President of Life Science Commercialization
FAIRFIELD, CT / ACCESSWIRE / July 30, 2024 / Envision Pharma Group (Envision) announced today the appointment of Bill Shirey...
Association of Dental Support Organizations Honors U.S. Oral Surgery Management
IRVING, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- The Association of Dental Support Organizations (ADSO) recognized U.S. Oral Surgery Management...
Interactive Strength Inc. (Nasdaq: TRNR) Secures Exclusive Distribution for CLMBR in Germany and Receives Six-Figure Initial Order
German Distributor placed six-figure initial order that is expected to ship in the third quarter of 2024Germany is the largest...
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology...
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to...
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced...
Canadian Red Cross announces financial assistance for people evacuated from Jasper due to wildfires in Alberta
$750 will be provided to households evacuated from their primary residence in JasperOTTAWA, July 30, 2024 (GLOBE NEWSWIRE) -- The...
Canadian Red Cross announces financial assistance for people evacuated from Jasper due to wildfires in Alberta
$750 will be provided to households evacuated from their primary residence in JasperOTTAWA, July 30, 2024 (GLOBE NEWSWIRE) -- The...
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
Audio Webcast schedule to be held on August 13, 2024 at 4:30 p.m. ETCELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE)...
Evoke Pharma, Inc. Announces Reverse Stock Split
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily...
Milestone Scientific Secures Key Patent Approvals in the U.S. and Europe
ROSELAND, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors
MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for...
Cassava Sciences Announces Expansion of Open-Label Extension Trials
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The...
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
Data shows L1-79 offers a statistically significant improvement compared to placebo in socialization, as well as the investigator- and parent-rated...
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the...